NASDAQ · AARD
Aardvark Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AARD: Nov 12, 2026
Aardvark Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.69. The reported EPS for the same quarter last year was $-0.75.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.69 | $-0.34 | $-1.07 | 8 |
| Dec 2026 | $-0.68 | $-0.42 | $-1.10 | 7 |
| Mar 2027 | $-0.58 | $-0.44 | $-0.68 | 3 |
| Jun 2027 | $-0.58 | $-0.43 | $-0.69 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Oct 30, 12:56 PM EDTWeekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals(RTTNews) – The biotech sector stayed active this week, with a mix of regulatory approvals, strategic partnerships, M&A activity, and clinical trial developments.
- RTTNews · Oct 23, 10:39 AM EDTFDA Lifts Clinical Hold On Aardvark's ARD-101; PWS Program Targets 2027(RTTNews) – Aardvark Therapeutics, Inc. (AARD) reported exploratory efficacy and safety data from its terminated Phase 3 HERO trial and open-label extension (OLE) study of ARD-101, an investigational treatment for hyperphagia associated with Prader-Willi syndrome (PWS). The compa
- RTTNews · Oct 22, 10:23 PM EDTFDA Lifts Clinical Hold On Aardvark's ARD-101 For Prader-Willi Syndrome; Stock Up 16%(RTTNews) – On Thursday, Aardvark Therapeutics, Inc. (AARD), a clinical-stage biopharmaceutical company, said that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on ARD-101 for hyperphagia in Prader-Willi syndrome.
- Zacks · Oct 21, 11:00 AM EDTAll You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to BuyAardvark Therapeutics, Inc. (AARD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- RTTNews · Aug 12, 8:27 AM EDTAardvark Evaluates ARD-101 HERO And OLE Data; Next Steps Expected In Q3 2026(RTTNews) – Aardvark Therapeutics, Inc. (AARD), a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics for hunger-related metabolic diseases, has reported its second-quarter 2026 financial results and provided business updates, with inv
- RTTNews · May 15, 9:38 AM EDTAardvark Therapeutics To Unblind Phase 3 HERO Data After FDA Issues Full Clinical Hold; Stock Down(RTTNews) – Aardvark Therapeutics, Inc (AARD) is preparing to unblind data from its Phase 3 HERO trial and its open-label extension after the U.S. FDA placed a full clinical hold on ARD-101, the company's investigational therapy for hyperphagia in Prader-Willi Syndrome. The decis
- RTTNews · Mar 24, 1:28 AM EDTAardvark Expects To Update On Paused Phase 3 Trial Of ARD-101 In Q2 2026; FY25 Net Loss Widens(RTTNews) – Aardvark Therapeutics, Inc.(AARD), a clinical-stage biopharmaceutical company, reported fourth-quarter and full-year 2025 financial results reflecting a wider net loss. In addition it provided pipeline and business updates for it's investigational drugs ARD-101 and AR
- RTTNews · Mar 6, 9:50 AM ESTWeekly Buzz: TBPH Cuts Jobs, ASND Gets FDA Nod, AARD Puts HERO On Hold, ESPR Opens Wallet(RTTNews) – The biotech sector delivered a mix of regulatory milestones, strategic deals, corporate restructuring and clinical trial developments across therapeutic areas such as hypothalamic obesity, peanut allergy, neurogenic orthostatic hypotension, and overweight and obesity
- RTTNews · Feb 27, 11:49 PM ESTAardvark Therapeutics Pauses Phase 3 Trial Of ARD-101 In Prader-Willi Syndrome; Stock Plunges(RTTNews) – Aardvark Therapeutics Inc. (AARD) announced that it has voluntarily paused the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO study is a randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of ARD-101
- RTTNews · Feb 12, 9:24 AM ESTAardvark Therapeutics Establishes Ardia Subsidiary To Advance Dermatology Pipeline(RTTNews) – Aardvark Therapeutics Inc. (AARD) announced on Thursday the formation of Ardia Therapeutics Inc., a wholly owned U.S. subsidiary focused on building a dermatology pipeline.
- Fintel · Dec 23, 7:02 AM ESTOppenheimer Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform RecommendationFintel reports that on December 23, 2025, Oppenheimer initiated coverage of Aardvark Therapeutics (NasdaqGS:AARD) with a Outperform recommendation. Analyst Price Forecast Suggests 127.45% Upside
- Fintel · Dec 12, 7:06 PM ESTWilliam Blair Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform RecommendationFintel reports that on December 12, 2025, William Blair initiated coverage of Aardvark Therapeutics (NasdaqGS:AARD) with a Outperform recommendation. Analyst Price Forecast Suggests 129.34% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Aardvark Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.